Biography
Dr. H. Richard Alexander is the Chief of Surgical Oncology and Director of the HIPEC Program at Rutgers Cancer Institute of New Jersey in New Brunswick. He is one of the most experienced peritoneal surface malignancy surgeons in the country, with extensive expertise in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Dr. Alexander trained in surgical oncology at the National Cancer Institute and has spent his career advancing the treatment of peritoneal cancers. His program at Rutgers is one of the leading HIPEC centers in the Northeast.
Education & Training
- Medical Degree — Georgetown University School of Medicine (Medicine)
- Residency — Hospital of the University of Pennsylvania (General Surgery)
- Fellowship — National Cancer Institute (Surgical Oncology)
Specialties & Procedures
Clinical Specialties
- Surgical Oncology
- Peritoneal Surface Malignancies
- HIPEC
Surgical Procedures
Board Certifications
- American Board of Surgery
Research Focus
Peritoneal surface malignancies, cytoreductive surgery with HIPEC for peritoneal mesothelioma, and regional chemotherapy delivery techniques.
Treatment Center
Dr. H. Richard Alexander practices at Rutgers Cancer Institute in New Brunswick, NJ.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is HIPEC surgery for peritoneal mesothelioma?
HIPEC involves surgically removing visible tumor from the abdominal cavity (cytoreductive surgery) and then bathing the area with heated chemotherapy to kill remaining microscopic cancer cells. Dr. Alexander is one of the most experienced HIPEC surgeons in the country for peritoneal mesothelioma.
Does Rutgers Cancer Institute have a dedicated HIPEC program?
Yes. Dr. Alexander directs the HIPEC Program at Rutgers Cancer Institute, which is one of the leading peritoneal surface malignancy programs in the Northeast United States.